FDA panel to review Vivus drug in July

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA is tentatively scheduled to review Vivus' obesity drug Qnexa July 15, 2010. The target date for the FDA to complete its review of the NDA is Oct. 28, 2010. Vivus release